Gonal-f

DRUG7 trials

Sponsors

Merck KGaA, Darmstadt, Germany, IBSA Institut Biochimique SA, Polymun Scientific GmbH, Glycotope GmbH, Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions

AnovulationFemale InfertilityHealthyInfertilityInfertility, Female

Phase 1

Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application

CompletedNCT01141270

Polymun Scientific GmbHHealthy

Start: 2009-01-31End: 2010-07-31Updated: 2010-08-04

Single Dose FSH-GEX™ in Healthy Volunteers

CompletedNCT01354886

Glycotope GmbHFemale Infertility

Start: 2011-04-30End: 2011-10-31Updated: 2021-05-11

Pergoveris FD and Liquid China BE Study

CompletedNCT04899193

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyHealthy

Start: 2021-05-08End: 2022-05-28Updated: 2022-06-15

Phase 3

Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF

CompletedNCT00378001

IBSA Institut Biochimique SAInfertility

Start: 2005-03-31End: 2006-05-31Target: 152Updated: 2015-02-16

Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation

CompletedNCT02335879

Changchun GeneScience Pharmaceutical Co., Ltd.Anovulation

Start: 2008-05-31Updated: 2015-01-12

A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China

CompletedNCT06173869

Ferring PharmaceuticalsInfertility, Female

Start: 2024-03-29End: 2025-05-31Updated: 2026-02-12

Phase 4

Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)

CompletedNCT00249834

Merck KGaA, Darmstadt, GermanyInfertility

Start: 2004-09-22End: 2006-01-16Updated: 2018-03-30

Related Papers

A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.

2017-08-0116 citations